PDS01ADC (Not yet branded)
Other Medications
Description
PDS01ADC is an antibody-drug conjugate (ADC) being developed for treatment of metastatic colorecral cancer, particularly in patients with microsatellite stable (MSS) tumors. This compound combines a targeted antibody with a cytotoxic payload to deliver chemotherapy directly to cancer cells. The drug is being evaluated in combination with hepatic artery infusion pump therapy and systemic treatments for liver-predominant metastatic disease.
Mechanism of Action
As an antibody-drug conjugate, PDS01ADC consists of a monoclonal antibody linked to a cytotoxic drug that binds to specific antigens expressed on colorectal cancer cells. Once the antibody binds to its target on the tumor cell surface, the entire complex is internalized, allowing the cytotoxic payload to be released in
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | IV |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.